BRAF inhibitors have revolutionized the treatment of V600E BRAF metastatic melanoma [147], but the rationale underlying the use of such inhibitors cannot explain a response in CRC patients because the molecular landscape is more complex and heterogeneous [148]. Here, BRAF is linked to colorectal carcinoma.